All Stories

  1. Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2017, Endocrine Society

    Dr. Michael W O'Reilly, Dr Niki Karavitaki, Prof Wiebke Arlt, GEORGIA NTALI, ashley grossman

  2. The prolactin receptor variant, Asn492Ile, results in activation of the Akt signalling pathway, and is found more frequently in patients with prolactinomas

    Article • Endocrine Abstracts, October 2016, Bioscientifica

    GEORGIA NTALI

  3. Management of multiple endocrine neoplasia type 1 (MEN1) and sporadic pancreatic neuroendocrine tumours (PNETS) in relation to the clinical guidelines: a single centre audit

    Article • Endocrine Abstracts, October 2016, Bioscientifica

    GEORGIA NTALI

  4. Childhood Hypothalamic and Pituitary Tumors∗

    Article • January 2016, Elsevier

    Dr Niki Karavitaki, GEORGIA NTALI

  5. Recent advances in the management of acromegaly

    Article • F1000Research, December 2015, Faculty of 1000, Ltd.

    Dr Niki Karavitaki, GEORGIA NTALI

  6. Faculty of 1000 evaluation for Outcomes of proton therapy for patients with functional pituitary adenomas.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  7. Faculty of 1000 evaluation for Stereotactic radiosurgery for acromegaly.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  8. Faculty of 1000 evaluation for Stereotactic Irradiation of GH-Secreting Pituitary Adenomas.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  9. Faculty of 1000 evaluation for Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  10. Faculty of 1000 evaluation for Place of cabergoline in acromegaly: a meta-analysis.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  11. Faculty of 1000 evaluation for The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  12. Faculty of 1000 evaluation for Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  13. Faculty of 1000 evaluation for Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  14. Faculty of 1000 evaluation for Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  15. Faculty of 1000 evaluation for Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  16. Faculty of 1000 evaluation for Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  17. Faculty of 1000 evaluation for Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  18. Faculty of 1000 evaluation for Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  19. Faculty of 1000 evaluation for Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  20. Faculty of 1000 evaluation for Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  21. Faculty of 1000 evaluation for Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  22. Faculty of 1000 evaluation for Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  23. Faculty of 1000 evaluation for Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  24. Faculty of 1000 evaluation for Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  25. Faculty of 1000 evaluation for Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  26. Faculty of 1000 evaluation for Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  27. Faculty of 1000 evaluation for Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  28. Faculty of 1000 evaluation for Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  29. Faculty of 1000 evaluation for Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  30. Faculty of 1000 evaluation for Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  31. Faculty of 1000 evaluation for Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

    Article • November 2015, Faculty of 1000, Ltd.

    GEORGIA NTALI

  32. Efficacy and Complications of Pituitary Irradiation

    Article • Endocrinology and Metabolism Clinics of North America, March 2015, Elsevier

    Dr Niki Karavitaki, GEORGIA NTALI

  33. Clinical and biochemical manifestations of Cushing’s

    Article • Pituitary, January 2015, Springer Science + Business Media

    Dr Niki Karavitaki, GEORGIA NTALI

  34. Functioning Gonadotroph Adenomas

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2014, Endocrine Society

    Dr Niki Karavitaki, GEORGIA NTALI

  35. Faculty of 1000 evaluation for Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients.

    Article • May 2014, Faculty of 1000, Ltd.

    GEORGIA NTALI

  36. Faculty of 1000 evaluation for Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests.

    Article • March 2014, Faculty of 1000, Ltd.

    GEORGIA NTALI

  37. Craniopharyngiomas: An Overview

    Article • January 2012, Springer Science + Business Media

    Dr Niki Karavitaki, MD Tim IM Korevaar, GEORGIA NTALI

  38. A Rare Case of a Male with 45, XO, SRY+, ZFY+ with Short Stature and Mild Turner Stigmata

    Article • Hormone Research in Paediatrics, January 2012, Karger Publishers

    GEORGIA NTALI

  39. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas

    Article • Endocrine, May 2011, Springer Science + Business Media

    GEORGIA NTALI

  40. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management

    Article • Clinical Endocrinology, March 2011, Wiley

    GEORGIA NTALI

  41. Serum Resistin and Hepatic Fat Content in Nondiabetic Individuals

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2006, Endocrine Society

    GEORGIA NTALI